カテゴリー： Market Monitor Global, 世界, 部品/材料

呼吸器疾患治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Respiratory Diseases Drugs Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY1706 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：74 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：化学＆材料

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Respiratory Diseases Drugs Market 調査レポートは次の情報を含め、グローバルにおけるの呼吸器疾患治療薬市場規模と予測を収録しています。・世界の呼吸器疾患治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の呼吸器疾患治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の呼吸器疾患治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「OTC」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

呼吸器疾患治療薬のグローバル主要企業は、Biogen、 Pfizer、 Teva、 Novartis、 Johnson & Johnson、 EliLilly、 Otsuka、 Merck、 AstraZeneca、 Novartis、 Takedaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、呼吸器疾患治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の呼吸器疾患治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の呼吸器疾患治療薬市場：タイプ別市場シェア、2022年
・OTC、Rx医薬品

世界の呼吸器疾患治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の呼吸器疾患治療薬市場：用途別市場シェア、2022年
・病院、小売薬局

世界の呼吸器疾患治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の呼吸器疾患治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における呼吸器疾患治療薬のグローバル売上、2018年-2023年
・主要企業における呼吸器疾患治療薬のグローバル売上シェア、2022年
・主要企業における呼吸器疾患治療薬のグローバル販売量、2018年-2023年
・主要企業における呼吸器疾患治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Biogen、 Pfizer、 Teva、 Novartis、 Johnson & Johnson、 EliLilly、 Otsuka、 Merck、 AstraZeneca、 Novartis、 Takeda

*************************************************************

・調査・分析レポートの概要
呼吸器疾患治療薬市場の定義
市場セグメント
世界の呼吸器疾患治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の呼吸器疾患治療薬市場規模
世界の呼吸器疾患治療薬市場規模：2022年 VS 2029年
世界の呼吸器疾患治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの呼吸器疾患治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の呼吸器疾患治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：OTC、Rx医薬品
呼吸器疾患治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、小売薬局
呼吸器疾患治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別呼吸器疾患治療薬市場規模 2022年と2029年
地域別呼吸器疾患治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Biogen、 Pfizer、 Teva、 Novartis、 Johnson & Johnson、 EliLilly、 Otsuka、 Merck、 AstraZeneca、 Novartis、 Takeda
...

We study the drugs for Respiratory Diseases
This report aims to provide a comprehensive presentation of the global market for Respiratory Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Diseases Drugs. This report contains market size and forecasts of Respiratory Diseases Drugs in global, including the following market information:
Global Respiratory Diseases Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Respiratory Diseases Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Respiratory Diseases Drugs companies in 2022 (%)
The global Respiratory Diseases Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
OTC Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Respiratory Diseases Drugs include Biogen, Pfizer, Teva, Novartis, Johnson & Johnson, EliLilly, Otsuka, Merck and AstraZeneca, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Respiratory Diseases Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Respiratory Diseases Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Respiratory Diseases Drugs Market Segment Percentages, by Type, 2022 (%)
OTC
Rx Drugs
Global Respiratory Diseases Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Respiratory Diseases Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Global Respiratory Diseases Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Respiratory Diseases Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Respiratory Diseases Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Respiratory Diseases Drugs revenues share in global market, 2022 (%)
Key companies Respiratory Diseases Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Respiratory Diseases Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Pfizer
Teva
Novartis
Johnson & Johnson
EliLilly
Otsuka
Merck
AstraZeneca
Novartis
Takeda
Outline of Major Chapters:
Chapter 1: Introduces the definition of Respiratory Diseases Drugs, market overview.
Chapter 2: Global Respiratory Diseases Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Respiratory Diseases Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Respiratory Diseases Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Respiratory Diseases Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Respiratory Diseases Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Respiratory Diseases Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Respiratory Diseases Drugs Overall Market Size
2.1 Global Respiratory Diseases Drugs Market Size: 2022 VS 2029
2.2 Global Respiratory Diseases Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Respiratory Diseases Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Respiratory Diseases Drugs Players in Global Market
3.2 Top Global Respiratory Diseases Drugs Companies Ranked by Revenue
3.3 Global Respiratory Diseases Drugs Revenue by Companies
3.4 Global Respiratory Diseases Drugs Sales by Companies
3.5 Global Respiratory Diseases Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Respiratory Diseases Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Respiratory Diseases Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Respiratory Diseases Drugs Players in Global Market
3.8.1 List of Global Tier 1 Respiratory Diseases Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Respiratory Diseases Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Respiratory Diseases Drugs Market Size Markets, 2022 & 2029
4.1.2 OTC
4.1.3 Rx Drugs
4.2 By Type – Global Respiratory Diseases Drugs Revenue & Forecasts
4.2.1 By Type – Global Respiratory Diseases Drugs Revenue, 2018-2023
4.2.2 By Type – Global Respiratory Diseases Drugs Revenue, 2024-2029
4.2.3 By Type – Global Respiratory Diseases Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Respiratory Diseases Drugs Sales & Forecasts
4.3.1 By Type – Global Respiratory Diseases Drugs Sales, 2018-2023
4.3.2 By Type – Global Respiratory Diseases Drugs Sales, 2024-2029
4.3.3 By Type – Global Respiratory Diseases Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Respiratory Diseases Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Respiratory Diseases Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.2 By Application – Global Respiratory Diseases Drugs Revenue & Forecasts
5.2.1 By Application – Global Respiratory Diseases Drugs Revenue, 2018-2023
5.2.2 By Application – Global Respiratory Diseases Drugs Revenue, 2024-2029
5.2.3 By Application – Global Respiratory Diseases Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Respiratory Diseases Drugs Sales & Forecasts
5.3.1 By Application – Global Respiratory Diseases Drugs Sales, 2018-2023
5.3.2 By Application – Global Respiratory Diseases Drugs Sales, 2024-2029
5.3.3 By Application – Global Respiratory Diseases Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Respiratory Diseases Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Respiratory Diseases Drugs Market Size, 2022 & 2029
6.2 By Region – Global Respiratory Diseases Drugs Revenue & Forecasts
6.2.1 By Region – Global Respiratory Diseases Drugs Revenue, 2018-2023
6.2.2 By Region – Global Respiratory Diseases Drugs Revenue, 2024-2029
6.2.3 By Region – Global Respiratory Diseases Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Respiratory Diseases Drugs Sales & Forecasts
6.3.1 By Region – Global Respiratory Diseases Drugs Sales, 2018-2023
6.3.2 By Region – Global Respiratory Diseases Drugs Sales, 2024-2029
6.3.3 By Region – Global Respiratory Diseases Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Respiratory Diseases Drugs Revenue, 2018-2029
6.4.2 By Country – North America Respiratory Diseases Drugs Sales, 2018-2029
6.4.3 US Respiratory Diseases Drugs Market Size, 2018-2029
6.4.4 Canada Respiratory Diseases Drugs Market Size, 2018-2029
6.4.5 Mexico Respiratory Diseases Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Respiratory Diseases Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Respiratory Diseases Drugs Sales, 2018-2029
6.5.3 Germany Respiratory Diseases Drugs Market Size, 2018-2029
6.5.4 France Respiratory Diseases Drugs Market Size, 2018-2029
6.5.5 U.K. Respiratory Diseases Drugs Market Size, 2018-2029
6.5.6 Italy Respiratory Diseases Drugs Market Size, 2018-2029
6.5.7 Russia Respiratory Diseases Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Respiratory Diseases Drugs Market Size, 2018-2029
6.5.9 Benelux Respiratory Diseases Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Respiratory Diseases Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Respiratory Diseases Drugs Sales, 2018-2029
6.6.3 China Respiratory Diseases Drugs Market Size, 2018-2029
6.6.4 Japan Respiratory Diseases Drugs Market Size, 2018-2029
6.6.5 South Korea Respiratory Diseases Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Respiratory Diseases Drugs Market Size, 2018-2029
6.6.7 India Respiratory Diseases Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Respiratory Diseases Drugs Revenue, 2018-2029
6.7.2 By Country – South America Respiratory Diseases Drugs Sales, 2018-2029
6.7.3 Brazil Respiratory Diseases Drugs Market Size, 2018-2029
6.7.4 Argentina Respiratory Diseases Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Respiratory Diseases Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Respiratory Diseases Drugs Sales, 2018-2029
6.8.3 Turkey Respiratory Diseases Drugs Market Size, 2018-2029
6.8.4 Israel Respiratory Diseases Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Respiratory Diseases Drugs Market Size, 2018-2029
6.8.6 UAE Respiratory Diseases Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Biogen
7.1.1 Biogen Company Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Respiratory Diseases Drugs Major Product Offerings
7.1.4 Biogen Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Biogen Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Respiratory Diseases Drugs Major Product Offerings
7.2.4 Pfizer Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Teva
7.3.1 Teva Company Summary
7.3.2 Teva Business Overview
7.3.3 Teva Respiratory Diseases Drugs Major Product Offerings
7.3.4 Teva Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Teva Key News & Latest Developments
7.4 Novartis
7.4.1 Novartis Company Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Respiratory Diseases Drugs Major Product Offerings
7.4.4 Novartis Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Novartis Key News & Latest Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Company Summary
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Respiratory Diseases Drugs Major Product Offerings
7.5.4 Johnson & Johnson Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Johnson & Johnson Key News & Latest Developments
7.6 EliLilly
7.6.1 EliLilly Company Summary
7.6.2 EliLilly Business Overview
7.6.3 EliLilly Respiratory Diseases Drugs Major Product Offerings
7.6.4 EliLilly Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.6.5 EliLilly Key News & Latest Developments
7.7 Otsuka
7.7.1 Otsuka Company Summary
7.7.2 Otsuka Business Overview
7.7.3 Otsuka Respiratory Diseases Drugs Major Product Offerings
7.7.4 Otsuka Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Otsuka Key News & Latest Developments
7.8 Merck
7.8.1 Merck Company Summary
7.8.2 Merck Business Overview
7.8.3 Merck Respiratory Diseases Drugs Major Product Offerings
7.8.4 Merck Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Merck Key News & Latest Developments
7.9 AstraZeneca
7.9.1 AstraZeneca Company Summary
7.9.2 AstraZeneca Business Overview
7.9.3 AstraZeneca Respiratory Diseases Drugs Major Product Offerings
7.9.4 AstraZeneca Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.9.5 AstraZeneca Key News & Latest Developments
7.10 Novartis
7.10.1 Novartis Company Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Respiratory Diseases Drugs Major Product Offerings
7.10.4 Novartis Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Novartis Key News & Latest Developments
7.11 Takeda
7.11.1 Takeda Company Summary
7.11.2 Takeda Respiratory Diseases Drugs Business Overview
7.11.3 Takeda Respiratory Diseases Drugs Major Product Offerings
7.11.4 Takeda Respiratory Diseases Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Takeda Key News & Latest Developments
8 Global Respiratory Diseases Drugs Production Capacity, Analysis
8.1 Global Respiratory Diseases Drugs Production Capacity, 2018-2029
8.2 Respiratory Diseases Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Respiratory Diseases Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Respiratory Diseases Drugs Supply Chain Analysis
10.1 Respiratory Diseases Drugs Industry Value Chain
10.2 Respiratory Diseases Drugs Upstream Market
10.3 Respiratory Diseases Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Respiratory Diseases Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Respiratory Diseases Drugs in Global Market
Table 2. Top Respiratory Diseases Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Respiratory Diseases Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Respiratory Diseases Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Respiratory Diseases Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Respiratory Diseases Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Respiratory Diseases Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Respiratory Diseases Drugs Product Type
Table 9. List of Global Tier 1 Respiratory Diseases Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Respiratory Diseases Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Respiratory Diseases Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Respiratory Diseases Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Respiratory Diseases Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Respiratory Diseases Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Respiratory Diseases Drugs Sales (K Units), 2024-2029
Table 16. By Application – Global Respiratory Diseases Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Respiratory Diseases Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Respiratory Diseases Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Respiratory Diseases Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Respiratory Diseases Drugs Sales (K Units), 2024-2029
Table 21. By Region – Global Respiratory Diseases Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Respiratory Diseases Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Respiratory Diseases Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Respiratory Diseases Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Respiratory Diseases Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Respiratory Diseases Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Respiratory Diseases Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Respiratory Diseases Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Respiratory Diseases Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Respiratory Diseases Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Respiratory Diseases Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Respiratory Diseases Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Respiratory Diseases Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Respiratory Diseases Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Respiratory Diseases Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Respiratory Diseases Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Respiratory Diseases Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Respiratory Diseases Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Respiratory Diseases Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Respiratory Diseases Drugs Sales, (K Units), 2024-2029
Table 46. Biogen Company Summary
Table 47. Biogen Respiratory Diseases Drugs Product Offerings
Table 48. Biogen Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Biogen Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Respiratory Diseases Drugs Product Offerings
Table 52. Pfizer Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Teva Company Summary
Table 55. Teva Respiratory Diseases Drugs Product Offerings
Table 56. Teva Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Teva Key News & Latest Developments
Table 58. Novartis Company Summary
Table 59. Novartis Respiratory Diseases Drugs Product Offerings
Table 60. Novartis Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Novartis Key News & Latest Developments
Table 62. Johnson & Johnson Company Summary
Table 63. Johnson & Johnson Respiratory Diseases Drugs Product Offerings
Table 64. Johnson & Johnson Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Johnson & Johnson Key News & Latest Developments
Table 66. EliLilly Company Summary
Table 67. EliLilly Respiratory Diseases Drugs Product Offerings
Table 68. EliLilly Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. EliLilly Key News & Latest Developments
Table 70. Otsuka Company Summary
Table 71. Otsuka Respiratory Diseases Drugs Product Offerings
Table 72. Otsuka Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Otsuka Key News & Latest Developments
Table 74. Merck Company Summary
Table 75. Merck Respiratory Diseases Drugs Product Offerings
Table 76. Merck Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Merck Key News & Latest Developments
Table 78. AstraZeneca Company Summary
Table 79. AstraZeneca Respiratory Diseases Drugs Product Offerings
Table 80. AstraZeneca Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. AstraZeneca Key News & Latest Developments
Table 82. Novartis Company Summary
Table 83. Novartis Respiratory Diseases Drugs Product Offerings
Table 84. Novartis Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Novartis Key News & Latest Developments
Table 86. Takeda Company Summary
Table 87. Takeda Respiratory Diseases Drugs Product Offerings
Table 88. Takeda Respiratory Diseases Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. Takeda Key News & Latest Developments
Table 90. Respiratory Diseases Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 91. Global Respiratory Diseases Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Respiratory Diseases Drugs Production by Region, 2018-2023 (K Units)
Table 93. Global Respiratory Diseases Drugs Production by Region, 2024-2029 (K Units)
Table 94. Respiratory Diseases Drugs Market Opportunities & Trends in Global Market
Table 95. Respiratory Diseases Drugs Market Drivers in Global Market
Table 96. Respiratory Diseases Drugs Market Restraints in Global Market
Table 97. Respiratory Diseases Drugs Raw Materials
Table 98. Respiratory Diseases Drugs Raw Materials Suppliers in Global Market
Table 99. Typical Respiratory Diseases Drugs Downstream
Table 100. Respiratory Diseases Drugs Downstream Clients in Global Market
Table 101. Respiratory Diseases Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Respiratory Diseases Drugs Segment by Type in 2022
Figure 2. Respiratory Diseases Drugs Segment by Application in 2022
Figure 3. Global Respiratory Diseases Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Respiratory Diseases Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Respiratory Diseases Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Respiratory Diseases Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Respiratory Diseases Drugs Revenue in 2022
Figure 9. By Type - Global Respiratory Diseases Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Respiratory Diseases Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Respiratory Diseases Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Respiratory Diseases Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Respiratory Diseases Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Respiratory Diseases Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Respiratory Diseases Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Respiratory Diseases Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Respiratory Diseases Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Respiratory Diseases Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Respiratory Diseases Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Respiratory Diseases Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Respiratory Diseases Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Respiratory Diseases Drugs Sales Market Share, 2018-2029
Figure 23. US Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Respiratory Diseases Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Respiratory Diseases Drugs Sales Market Share, 2018-2029
Figure 28. Germany Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Respiratory Diseases Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Respiratory Diseases Drugs Sales Market Share, 2018-2029
Figure 37. China Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Respiratory Diseases Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Respiratory Diseases Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Respiratory Diseases Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Respiratory Diseases Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Respiratory Diseases Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Respiratory Diseases Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Respiratory Diseases Drugs by Region, 2022 VS 2029
Figure 54. Respiratory Diseases Drugs Industry Value Chain
Figure 55. Marketing Channels

※参考情報

呼吸器疾患治療薬は、主に肺や気道に影響を与えるさまざまな疾患に対する治療薬を指します。これらの疾患には、喘息、慢性閉塞性肺疾患（COPD）、肺炎、アレルギー性鼻炎、肺結核などが含まれます。呼吸器疾患治療薬は、これらの状態を管理し、患者の生活の質を向上させるために重要な役割を果たします。

呼吸器疾患の特徴として、症状の多様性が挙げられます。喘息のような慢性的な状態では、呼吸が困難で、咳や喘鳴が見られます。また、COPDは長期にわたる喫煙や有害物質の吸入によって引き起こされることが多く、慢性的な咳や痰、息切れを伴います。肺炎や感染症も呼吸器疾患の一部であり、これも他の疾患とは異なる症状を示します。これらの疾患に対する治療薬は、それぞれの病態生理に応じた機序を持っています。

主な種類としては、気管支拡張薬、抗炎症薬、抗生物質、抗アレルギー薬、免疫抑制剤などがあります。気管支拡張薬は、主に気道を広げて呼吸を楽にするために使用されます。β2アドレナリン受容体作動薬（SABA）や長時間作用型β2作動薬（LABA）が典型的です。これらは喘息やCOPDの急性症状の緩和に用いられます。

抗炎症薬は、主にコルチコステロイドが代表的で、気道の炎症を抑える効果があります。特に喘息やCOPDの管理において、長期的な管理薬として利用されます。抗生物質は、細菌感染による肺炎などの治療に必須です。炎症が原因の疾患に対する治療薬としては、気管支拡張薬と併せて用いることが一般的です。

抗アレルギー薬は、アレルギー性鼻炎や喘息患者に対して使用され、ヒスタミン受容体拮抗薬やロイコトリエン受容体拮抗薬が含まれます。これにより、アレルギー反応を抑え、症状の緩和が図られます。免疫抑制剤は、重度の喘息や自己免疫性疾患に対する治療として用いられることがあります。

用途に関しては、これらの薬剤は急性発作の治療や、慢性的な疾患の管理に広範囲に使用されます。特に、喘息やCOPD患者にとって、定期的な治療と急性症状の緩和は日常生活において非常に重要です。これらの薬剤は、単独または組み合わせて使用されることがあります。

呼吸器疾患の治療における関連技術も重要です。例えば、吸入器は、患者が薬剤を直接気道に送達するために使用するデバイスです。吸入器には、メータードース（MDI）やドライパウダー吸入器（DPI）、噴霧吸入器など、さまざまなタイプがあります。これにより、薬剤が効果的に肺に届くことが期待されます。また、吸入器の使用に関する教育も重要であり、正しい使用法を指導することが患者のコンプライアンス向上に寄与します。

さらに、生物学的製剤の登場により、重症喘息の治療に革命が起きていることも特筆すべき点です。これらの薬剤は、特定の炎症性経路をターゲットとし、従来の治療薬では対応しきれない患者に新たな治療の選択肢を提供します。特に、抗IL-5抗体や抗IL-4抗体などが利用され、これにより患者の管理は一層向上しています。

最後に、呼吸器疾患治療薬の研究開発においては、ゲノム医療や個別化医療の進展も影響を与えています。患者の遺伝子情報に基づいて治療方針を決定することが可能になっており、これにより治療効果の向上を目指すアプローチが進んでいます。

呼吸器疾患治療薬は、さまざまな疾患に対する多様なアプローチを提供し、患者の生活を支える重要な役割を果たしています。今後も新たな治療薬や技術が登場し、さらに多くの患者に対して効果的な治療が提供されることが期待されています。呼吸器疾患は広範な問題であり、その科学的理解と新たな治療方法の開発は、医療の現場において重要な課題です。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 呼吸器疾患治療薬の世界市場見通し2023年-2029年(Respiratory Diseases Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

呼吸器疾患治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp